Focus:
Central Nervous System
-
23 July 2020 Analysis
Breaking the blood brain barrier: neurology’s greatest challenge
The blood-brain barrier protects the brain from dangerous pathogens and toxins but is notoriously difficult to penetrate with medications. Chloe Kent finds out more about the difficulties of overcoming this...
-
14 July 2020 Analysis
Treating social anxiety disorder: VistaGen and EverInsight collaborate in Asian markets
VistaGen and EverInsight have signed a development and commercialisation agreement for the former’s first-in-class drug for social anxiety disorder. The deal focuses on the Greater China, South Korea and Southeast...
-
25 June 2020 News
Yumanity Therapeutics signs drug development deal with Merck
US-based Yumanity Therapeutics has signed a research collaboration and licence agreement with Merck (MSD) to develop new therapies for neurodegenerative diseases.
-
20 March 2020 whitepapers
Case Study: Bristol-Myers Squibb
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company headquartered in New York City that specialises in discovering, developing and delivering innovative medicines for patients with serious diseases.
-
11 March 2020 Comment
Multiple sclerosis awareness month brings new research and treatments
March is multiple sclerosis (MS) awareness month and this year the aim is to focus on the global awareness and understanding of the disease. Throughout the month, multiple sclerosis will...
-
6 March 2020 projects
Audentes’ Gene Therapy Manufacturing Facility, Sanford, North Carolina
Audentes Therapeutics, a genetic medicines company, is planning to build a gene therapy manufacturing facility in Sanford, North Carolina, US.
-
4 March 2020 Analysis
A resolution for the new decade: resolve the US opioid crisis
In 2019, the opioid crisis in the US reached its peak. It dominated the news and legislative agenda and two pharma companies declared bankruptcy as a result of multiple legal...
-
28 February 2020 News
Biogen and Sangamo to develop neurological disease drugs
Biogen and Sangamo Therapeutics have signed a global licensing agreement for the development of drugs to treat neurological diseases, including Alzheimer’s and Parkinson’s diseases.
-
25 February 2020 Comment
Higher prevalence of epilepsy in low and middle-income countries
Epilepsy is a common neurological condition where abnormal activity in the brain leads to seizures. This condition is usually diagnosed after a person has experienced two or more unprovoked seizures....
-
11 February 2020 Company News
Lilly and Genentech announce two failures in Alzheimer’s disease prevention study
Eli Lilly has announced its drug solanezumab failed to meet its primary endpoint in the Phase II/III Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) study.